Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.520
-0.050 (-3.18%)
Feb 11, 2026, 4:00 PM EST - Market closed

Metagenomi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21
57135---
Enterprise Value
-85-93---
Last Close Price
1.523.61---
PS Ratio
1.832.58---
PB Ratio
0.320.57---
P/TBV Ratio
0.320.57---
Debt / Equity Ratio
0.230.200.220.071.11
Debt / FCF Ratio
---1.182.29
Asset Turnover
0.100.150.120.06-
Quick Ratio
6.306.733.997.494.32
Current Ratio
6.426.914.047.564.33
Return on Equity (ROE)
-40.87%-34.69%-28.04%-27.62%-
Return on Assets (ROA)
-19.02%-16.12%-12.59%-10.03%-
Return on Capital Employed (ROCE)
-42.30%-30.90%-26.50%-12.20%-20.50%
Earnings Yield
-155.49%-57.78%---
FCF Yield
-161.98%-83.04%---
Buyback Yield / Dilution
-51.55%-870.10%-0.15%40.27%-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q